Sofosbuvir
- Generic Name
- Sofosbuvir
- Brand Names
- Epclusa, Harvoni, Sovaldi, Vosevi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FN3O9P
- CAS Number
- 1190307-88-0
- Unique Ingredient Identifier
- WJ6CA3ZU8B
- Background
Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, ...
- Indication
Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa.
...
- Associated Conditions
- Chronic Hepatitis C - Genotype 3, Chronic Hepatitis C Genotype 1, Chronic Hepatitis C Virus (HCV) Infection, Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 2, Chronic hepatitis C genotype 5, Genotype 4 Chronic Hepatitis C, Genotype 6 chronic hepatitis C infection
- Associated Therapies
- -
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
- Conditions
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT02175966
- Locations
- 🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸Indiana University Health - University Hospital, Indianapolis, Indiana, United States
🇺🇸Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
The SIM-SOF Trial for Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Center For Hepatitis C, Atlanta, GA
- Target Recruit Count
- 93
- Registration Number
- NCT02168361
- Locations
- 🇺🇸
Center for Hepatitis C, Atlanta, Georgia, United States
An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant
- First Posted Date
- 2014-06-17
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT02165189
A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C
- Conditions
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT02161939
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇺🇸Piedmont Transplant, Atlanta, Georgia, United States
Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 143
- Registration Number
- NCT02133131
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2018-04-27
- Target Recruit Count
- 44
- Registration Number
- NCT02128217
- Locations
- 🇺🇸
7804 Weill Cornell Chelsea CRS, New York, New York, United States
🇺🇸2701 Northwestern University CRS, Chicago, Illinois, United States
🇺🇸Rush Univ. Med. Ctr. ACTG CRS (2702), Chicago, Illinois, United States
Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 66
- Registration Number
- NCT02128542
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Janssen Infectious Diseases BVBA
- Target Recruit Count
- 310
- Registration Number
- NCT02114177
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Janssen Infectious Diseases BVBA
- Target Recruit Count
- 103
- Registration Number
- NCT02114151
EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C
- Conditions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT02097966
- Locations
- 🇬🇧
Local Institution, Wrexham, United Kingdom
🇬🇧Local Instituition, Liverpool, Merseyside, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.